News

TEVA

​Allergan: Botox and Beyond in Biotech

MoneyShow | Equities.com |

What's the drug giant been up to?


​As Sam Sees It: Two Sectors With Near-Term Volatilty and Long-Term Opportunity

Sam Stovall | Equities.com |

Those expecting oil's big pop to last may be left disappointed.


​VBI Vaccines' Backers Set It Apart In The Infectious Disease Space

Samuel Rae | Equities.com |

When evaluating a biotech company, the backers often tell the tale...


​EpiPen Pricing: Much Ado About Nothing

Guild Investment Management | Equities.com |

How has Mylan enjoyed such market dominance and pricing power on a drug long been out of patent?


5 Biotch Stocks to Watch for a Winning Strategy

The Life Sciences Report | Equities.com |

Maxim Group Equity Analyst Jason McCarthy has developed a biotechnology theme that leverages immunotherapy platforms serving both cancer and infectious disease indications. It's an elegant


Bulls Emerge Victorious in July

Adam Sarhan | Equities.com |

July 2015 was a volatile month, as investors had to navigate two potential external shocks (Greece and China) and digest the latest round of economic and earnings data. After all was said and


Beyond Biotech: New Areas Investors Can Profit from in Life Sciences

The Life Sciences Report | Equities.com |

Analyst Pooya Hemami of Edison Investment Research casts a wide net when it comes to investment opportunities in the life sciences. You name it, his universe includes it: artificial sweeteners,


And That Was the Week That Was - 5/26/15 to 5/29/15

Joel Anderson | Equities.com |

Here's a look back at the last week in the markets... The Week in Major Indices S&P 500:


Stocks Rally During Heart of Earnings Season

Adam Sarhan | Equities.com |

Stocks rallied last week as investors digested the latest round of largely lackluster economic and earnings data. The big winners (so far) from earnings season include: Amazon.com ($AMZN), Netflix


5 Biotech Stocks That Could Double or Triple for Investors

The Life Sciences Report | Equities.com |

For Keith Markey of Griffin Securities, the science is paramount. Without understanding the underlying basis for activity, safety and efficacy, there's just no betting on a biotech stock. Over


Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     

Blockchain in Digital Identity - Discussion at the EU Parliament

From the recent Blockchain For Europe Summit in Brussels: Panel on Digital Identity